SCHEMBL190970

SCHEMBL190970

CCOC(=O)c1ccc(Cl)c(Oc2cc(Nc3nc(CCc4ccccc4)cs3)ncc2Br)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.40
MAPT P10636 7/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GCK P35557 3/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
P2RY12 Q9H244 1/20 0.36
RAB9A P51151 5/20 0.36
NPC1 O15118 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
CASP3 P42574 1/20 0.36
SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL192236 0.91 GCK (0.41) MAPTMEN1KMT2AGCKRAB9A
Hydrochloric Acid SCHEMBL190741 0.81 MCHR1 (0.41) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL191430 0.77 LMNA (0.46) MAPTMEN1KMT2AALDH1A1CYP2C9
SCHEMBL190933 0.76 GCK (0.41) GCKRAB9ANPC1SMN1; SMN2AOC3
SCHEMBL12305712 0.76 GCK (0.41) MAPTGCKRAB9ANPC1SMN1; SMN2
SCHEMBL191030 0.76 GCK (0.44) GCKALDH1A1SMN1; SMN2AOC3
SCHEMBL191480 0.75 GCK (0.54) GCKAOC3
SCHEMBL191341 0.75 MEN1 (0.43) MAPTMEN1KMT2AGCKALDH1A1
SCHEMBL191677 0.75 GCK (0.45) TRPV4MAPTMEN1KMT2AGCK
SCHEMBL192244 0.74 GCK (0.44) MEN1KMT2AGCKRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 TRPV4 4775/4885MAPT 4375/4885MEN1 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.